Table 2.
Clinical features | n | Marrow CR, n (%) | UVA |
MVA |
Median survival, months | UVA |
MVA |
||
---|---|---|---|---|---|---|---|---|---|
p | OR | p | p | HR | p | ||||
Platelets, × 109/l | |||||||||
<100 | 71 | 35 (49) | <0.001 | 11.5 | 0.03 | 5.0 | <0.001 | NA | NS |
⩾100 | 18 | 17 (94) | NR | ||||||
ABC, × 109/l | |||||||||
<1.0 | 58 | 43 (74) | <0.001 | 6.8 | <0.001 | 7.8 | <0.001 | 1.7 | 0.02 |
⩾1.0 | 31 | 9 (29) | 4.3 | ||||||
Dose schedule | |||||||||
Weekly | 40 | 24 (60) | 0.79 | NA | NA | 9.5 | 0.03 | NA | NS |
Single dose | 49 | 28 (57) | 5.0 | ||||||
Treatment status | |||||||||
Salvage 1 | 29 | 22 (76) | 0.02 | NA | NS | 10.2 | <0.001 | 2.3 | 0.007 |
>Salvage 1 | 60 | 30 (50) | 4.8 | ||||||
Karyotype | |||||||||
Diploid | 17 | NS | 0.05 | NA | NS | 44.0 | <0.001 | 2.9 | 0.01 |
Other | 10 | ||||||||
Complex | 24 | 5.0 | |||||||
Abnormal Ch 17 | 11 | ||||||||
Ph-positive | 17 | ||||||||
Translocation (4;11) | 9 |
ABC, peripheral blood absolute blast count; Ch: chromosome; CR, complete response; HR, hazard ratio; MVA, multivariate analysis; Ph: Philadelphia chromosome; NA, not applicable; NR, not reported; NS, not significant; OR, odds ratio; UVA, univariate analysis.